OncologyTube.com is the first and only free video sharing website dedicated to helping oncology professionals spread knowledge about cancer research through video, audio and other multimedia.
    • OncologyTube Cancer Articles, News and Videos

      Site: OncologyTube Cancer Articles, News and Videos

    • Products & Pricing
      • Banner Advertising Plans
      • eNewsletter Packages
      • Pre-Roll Advertising
      • Create A Deep Dive Conversation
      • Create a Video Release (VR)
      • Boost Earned Media Only $60
    • 0
      • Portuguese
      • Spanish
      • Italian
      • Greek (Greece)
      • Sinhala
      • Polish
      • Arabic (Saudi Arabia)
      • Swedish (Sweden)
      • Portuguese (Brazil)
      • Hindi (India)
      • English (Australia)
      • Hebrew (Israel)
      • Czech
      • Chinese
      • Turkish
      • Japanese (Japan)
      • Dutch
      • French
      • German
      • Chinese (Traditional Han, Taiwan)
      • Korean (South Korea)
      • Thai
      • Spanish (Chile)
      • English (United States)
      • Russian
      • Danish (Denmark)
  • Home
  • Trending

  • Login

  • Quick Links
  • Schedule A Remote Interview!
  • Check Out Our Blog
  • Buy Advertising Banners
  • Buy Pre-Roll Advertisements
  • Boost Your Earned Media starting at Just $60
  • Create A Deep Dive Conversation
  • Advertising Specifications
  • Our Editorial Process

  • Audio and Video
  • Videos
  • Audio

  • Channels
  • Browse Channels

  • Categories
  • Acute Lymphoblastic Leukemia 5588
  • Acute Myelogenous Leukemia 222
  • Bladder 96
  • Bone Metastases 5
  • Brain 79
  • Breast 523
  • Business Management 5
  • Cervical 16
  • Chronic Lymphocytic Leukemia 208
  • Chronic Myelogenous Leukemia 54
  • Colorectal 169
  • Conference Coverage 1
  • COVID-19 43
  • Gastrointestinal 177
  • General 341
  • Genitourinary 3
  • Head and Neck 110
  • Help 3
  • Hematologic Malignancies 204
  • Hodgkin Lymphoma 31
  • Imaging 2
  • Immunotherapy 179
  • Kidney 392
  • Liver 40
  • Lung 89
  • Lymphoma 232
  • Melanoma and Skin 107
  • Multiple Myeloma 533
  • Myeloproliferative Disease 37
  • News 149
  • Non-Hodgkin Lymphoma 81
  • Non-Small Cell Lung Cancer 551
  • Other 517
  • Ovarian 65
  • Pancreatic 100
  • Patient Resources 51
  • Pediatric 7
  • Prostate 300
  • Sarcoma 13
  • Sickle Cell 22
  • Small Cell Lung Cancer 81
  • Supportive Care 51
  • Testicular 3
  • Urology 16
  • Uterine 9

  • Install
  • Play a Link
  • About
  • Contact
  • Acute Lymphoblastic Leukemia
  • Acute Myelogenous Leukemia
  • Bladder
  • Bone Metastases
  • Brain
  • Breast
  • Business Management
  • Cervical
  • Chronic Lymphocytic Leukemia
  • Chronic Myelogenous Leukemia
  • Colorectal
  • Conference Coverage
  • COVID-19
  • Gastrointestinal
  • General
  • Genitourinary
  • Head and Neck
  • Help
  • Hematologic Malignancies
  • Hodgkin Lymphoma
  • Imaging
  • Immunotherapy
  • Kidney
  • Liver
  • Lung
  • Lymphoma
  • Melanoma and Skin
  • Multiple Myeloma
  • Myeloproliferative Disease
  • News
  • Non-Hodgkin Lymphoma
  • Non-Small Cell Lung Cancer
  • Other
  • Ovarian
  • Pancreatic
  • Patient Resources
  • Pediatric
  • Prostate
  • Sarcoma
  • Sickle Cell
  • Small Cell Lung Cancer
  • Supportive Care
  • Testicular
  • Urology
  • Uterine
Shilpa Gupta, MD @Shilpaonc @ClevelandClinic @CleClinicNews #ASCOGU22 GU22#PARADIGM #mUC Phase III PARADIGM Study
0:07:44

Shilpa Gupta, MD @Shilpaonc @ClevelandClinic @CleClinicNe...

Shilpa Gupta, MD, Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic. In this video, she speaks about the ASCO GU 2022 Abstract - Disease management and frontline treatment of locally advanced or metastatic urothelial (la/mUC) carcinoma: The U.S. physician PARADIGM study.

Origins:

The therapy options for la/mUC are changing. There is a scarcity of data on current la/mUC therapy patterns. Using qualitative interviews, this study examined physician treatment decision-making and prescribing trends in the United States (QIs).

Methodologies:

First, published abstracts from January 2018 to March 2021 were reviewed using a targeted literature search (TLS). The TLS findings were then used to perform QIs with 15 US medical oncologists/urologists in July 2021. Physicians were asked to participate in a 60-minute, one-on-one phone interview. Physicians are required to be board-certified oncologists/urologists who have managed 1 la/mUC patients who had had first-line (1L) systemic therapy in the previous 6 months.

Outcomes:

Seven retrospective studies published in the United States indicated low usage of 1L systemic therapy, with 40 percent to 65 percent of la/mUC patients not being treated; substantial attrition rates were noted, with only 15 percent to 40 percent of 1L patients receiving second-line (2L) medication. The TLS only contained patient data from 2017 onwards, and it did not cover current systemic therapy patterns for newly licensed medications. Community oncologists (n = 8), academic oncologists (n = 4), and community urologists (n = 3) were among the QI respondents. In the previous six months, each physician saw an average of 23 la/mUC patients. According to doctors, around 75% of la/mUC patients are now receiving systemic therapy, with all oncologists recommending 1L immunotherapy (IO) maintenance to eligible patients (n = 10 prescribing avelumab for 90%). With the availability of IO and innovative medicines, 11 respondents (73%) believe that the proportion of systemic-treated patients has increased in recent years. Poor performance status (73 percent), old age (67 percent), patient preference (53 percent), and comorbidities were the top reasons for not recommending systemic therapy (47 percent ). According to physician reports, 41% of 1L regimens were carboplatin-based, 37% were cisplatin-based, 17% were single-agent IO, and 4% were nonplatinum chemotherapy. Renal function (100%), performance status (75%), neuropathy (75%), and age were the most important factors in deciding on a 1L regimen (50 percent ). Patients who were platinum ineligible or who declined chemotherapy were usually given IO. According to ten oncologists, 60 percent to 80 percent of 1L la/mUC patients were given a 2L treatment.

Observations:

Physicians reported greater treatment rates from the QIs than from the TLS; however, our physician sample was small, and the TLS only included patient data up to 2017, so it does not reflect current systemic treatment practices. Due to increasing treatment choices after 2017, the number of US la/mUC patients treated with/eligible for 1L systemic therapy has increased over time, including IO maintenance and subsequent lines. The next step in this research will be a quantitative survey of 150 medical oncologists.

56 Views
11 months Ago
Genitourinary GU Cancer Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Genitourinary Description
Genitourinary Cancer such as prostate cancer, kidney cancer, bladder cancer, testicular cancer and cancers of the penis.

ASCO 2022 Genitourinary Cancer Question & Answer
0:02:16
ASCO 2022 Genitourinary Cancer Question & Answer
8 Views
4 months Ago
MOASC
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
ASCO [2022] Genitourinary Cancer: MOASC Oncology Spotlight
0:21:37
ASCO [2022] Genitourinary Cancer: MOASC Oncology Spotlight
190 Views
4 months Ago
MOASC
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Shilpa Gupta, MD @Shilpaonc @ClevelandClinic @CleClinicNews #ASCOGU22 GU22#PARADIGM #mUC Phase III PARADIGM Study
0:07:44
Shilpa Gupta, MD @Shilpaonc @ClevelandClinic @CleClinicNe...
56 Views
11 months Ago
Genitourinary GU Cancer Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Copyright 2023 Medicus Networks, Inc. 45121 Morgan Heights Rd. Temecula, CA 92592